高管在强劲盈利和积极分析师前景下，出售了303.6万美元的Travere Therapeutics股票。 Executives sold $3.036M in Travere Therapeutics stock amid strong earnings and positive analyst outlook.

2025年12月24日, Travere治疗内幕人士William Rote和Jula Inrig分别出售了60 000股和15 000股,共计30.36万美元。 On December 24, 2025, Travere Therapeutics insiders William Rote and Jula Inrig sold 60,000 and 15,000 shares respectively, totaling $3.036 million. 销售量减少了37%和14%,Rote的剩余股份价值407万美元。 The sales reduced their stakes by 37% and 14%, with Rote’s remaining holdings valued at $4.07 million. 该公司在10月30日报告Q3结果强劲,EPS为0.28美元,超过预期,年收入比预期增长162%,达1.6486亿美元。 The company reported strong Q3 results on October 30, with $0.28 EPS, surpassing expectations, and revenue up 162% year-over-year to $164.86 million. 尽管股本和净差值出现负回报,但12月29日股票结账为38.88美元,分析师的评级是“Moderate Buy”,目标价格为38.71美元。 Despite a negative return on equity and net margin, the stock closed at $38.88 on December 29, with analysts maintaining a “Moderate Buy” rating and a target price of $38.71.